AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
Portfolio Pulse from Vandana Singh
AstraZeneca plc (NASDAQ:AZN) has entered into a partnership with Absci Corporation (NASDAQ:ABSI) to develop an AI-driven antibody for cancer treatment, with a deal value of up to $247 million. Absci will receive an upfront fee, R&D funding, milestone payments, and royalties on product sales. The collaboration aims to leverage Absci's AI technology for protein analysis to accelerate drug discovery. This move is part of a broader trend of incorporating AI into pharmaceutical research, as seen with Genentech's recent partnership with NVIDIA Corporation (NASDAQ:NVDA). ABSI stock rose 8.62% in premarket trading.
December 04, 2023 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Absci's stock rose 8.62% in premarket trading following the announcement of the partnership with AstraZeneca, indicating a positive market reaction.
The significant premarket stock price increase reflects investor optimism about the deal's financial benefits and Absci's role in the partnership, suggesting a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
AstraZeneca's partnership with Absci could enhance its drug discovery capabilities and strengthen its position in the cancer treatment market.
The partnership with Absci is likely to be viewed positively as it could lead to the development of innovative cancer treatments, potentially improving AstraZeneca's market position and future revenue streams.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
NVIDIA's recent collaboration with Genentech for AI research programs may gain increased attention due to the industry trend of AI integration in pharmaceuticals.
While not the main focus of the article, NVIDIA's mention in the context of a similar AI-pharma partnership could positively influence investor perception of its growth potential in this sector.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Roche Holdings AG, through its subsidiary Genentech, is also engaging in AI partnerships, which may reflect positively on its innovation strategy.
Roche is mentioned passively in relation to Genentech's AI partnership, which may have a neutral short-term impact as it is not the primary focus of the news.
CONFIDENCE 60
IMPORTANCE 40
RELEVANCE 30